About Marea Therapeutics
Marea Therapeutics is a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases. Its lead program, MAR001, is a monoclonal antibody targeting ANGPTL4 in Phase 2 clinical development for adults with metabolic dysfunction and high cardiovascular disease risk. The company is also advancing MAR002 for the treatment of acromegaly.
Company details
Funding
Total raised
$190M
Last stage
Series B
Investors
Founders
Josh Lehrer
MD, M.Phil., FACC. CEO of Marea since October 2023. Previously CEO of Graphite Bio (merged with LENZ Therapeutics) and held leadership roles at Global Blood Therapeutics.
Ethan J. Weiss
MD. Scientific co-founder and CSO of Marea Therapeutics. Quoted as co-founder and CSO in multiple press releases and company announcements.
Joshua Rabinowitz
MD, PhD. Professor of Chemistry & Integrative Genomics at Princeton University. Scientific co-founder of Marea Therapeutics.
Charles Homcy
Partner Emeritus at Third Rock Ventures and UCSF professor; instrumental in incubating Marea Therapeutics at Third Rock.
What happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.